Establishment Labs Holdings Inc. (NASDAQ:ESTA) Holdings Decreased by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 38.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 554,061 shares of the company's stock after selling 349,354 shares during the quarter. JPMorgan Chase & Co. owned about 1.98% of Establishment Labs worth $25,526,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Establishment Labs during the 4th quarter worth about $36,000. KLP Kapitalforvaltning AS bought a new stake in Establishment Labs during the fourth quarter worth approximately $161,000. Handelsbanken Fonder AB lifted its position in Establishment Labs by 32.3% in the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock worth $378,000 after purchasing an additional 2,000 shares during the period. Verition Fund Management LLC boosted its stake in Establishment Labs by 22.8% during the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company's stock valued at $407,000 after purchasing an additional 1,746 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in Establishment Labs by 32.5% during the 3rd quarter. HighTower Advisors LLC now owns 10,311 shares of the company's stock valued at $446,000 after purchasing an additional 2,529 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA traded up $0.20 on Friday, reaching $30.34. 720,554 shares of the company traded hands, compared to its average volume of 448,703. The stock has a market capitalization of $875.19 million, a PE ratio of -11.76 and a beta of 0.77. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. The company's 50 day moving average is $36.44 and its 200-day moving average is $40.10. Establishment Labs Holdings Inc. has a fifty-two week low of $26.56 and a fifty-two week high of $60.12.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to analysts' expectations of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. As a group, analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens restated an "overweight" rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $57.40.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.